Monitoring Test Helps Guide Inflammatory Bowel Disease Management
|
By LabMedica International staff writers Posted on 31 Jul 2012 |
|
A new generation test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients who use infliximab.
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Automated Clinical Chemistry Analyzer
Envoy 500+
Latest Immunology News
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read more
Molecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Microbiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
Technology
view channel
Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Chemotherapy selection for breast cancer is challenged by heterogeneous tumor responses. Conventional chemosensitivity assays can be slow, require large sample volumes, and struggle with complex biological... Read more
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Industry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more
